嘉事堂药业股份有限公司 本公司及监事会全体成员保证信息披露的内容真实、准确、完 证券代码：002462 证券简称：嘉事堂 公告编号：2025-20 整，没有虚假记载、误导性陈述或重大遗漏。 一、股东大会审议通过利润分配方案情况 润分配方案为：以公司截至 2024 年 12 月 31 日的总股本为基数，每 10 股派发现 金红利 1.7 元（含税），不送红股，不以公积金转增股本。 若在分配预案实施前公司总股本由于可转债转股、股份回购、股权激励行权、 再融资新增股份上市等原因发生变化的，按照分配比例不变的原则对分配总额进 行调整。 两个月。 二、本次实施的利润分配方案 本公司 2024 年年度权益分派方案为：以公司现有总股本 291,707,120 股为 基数，向全体股东每 10 股派 1.70 元人民币现金（含税；扣税后，QFII、RQFII 以及持有首发前限售股的个人和证券投资基金每 10 股派 1.53 元；持有首发后限 售股、股权激励限售股及无限售流通股的个人股息红利税实行差别化税率征收， 本公司暂不扣缴个人所得税，待个人转让股票时，根据其持股期限计算应纳税额 【注】；持有首发后限售股、股权激励限售股及无 ...

2024年度权益分派实施公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、股东大会审议通过利润分配方案情况 1、嘉事堂药业股份有限公司（以下简称"公司"或"本公司"）2024 年度利 润分配方案为：以公司截至 2024 年 12 月 31 日的总股本为基数，每 10 股派发现 金红利 1.7 元（含税），不送红股，不以公积金转增股本。 若在分配预案实施前公司总股本由于可转债转股、股份回购、股权激励行权、 再融资新增股份上市等原因发生变化的，按照分配比例不变的原则对分配总额进 行调整。 上述利润分配方案已获 2025 年 5 月 19 日召开的 2024 年度股东大会审议通 过，具体内容详见公司指定信息披露媒体《中国证券报》、《证券时报》与巨潮资 讯网（http://www.cninfo.com.cn）于 2025 年 5 月 20 日发布的《2024 年度股 东大会决议公告》（公告编号：2025-19）。 2、自 2024 年年度权益分配方案披露至实施期间，公司股本总额未发生变化。 3、本次实施的利润分配方案与 2024 年年度股东大会审议通过的利润分 ...

北京市安理律师事务所 关于嘉事堂药业股份有限公司 2024 年度股东大会的法律意见书 文件编号：安理法意（2025）嘉字第 051901 号 致：嘉事堂药业股份有限公司 1. 本法律意见书仅对出具日以前与本次股东大会有关的问题发表意见，并 不对有关会计、审计等专业事项发表意见。 2. 本法律意见书制作过程中，承办律师已按照中国现行法律、法规的要求， 对与出具本法律意见书有关的文件资料进行了必要审查。 3. 承办律师在出具法律意见书之前，已得到嘉事堂的承诺和保证，即公司 向承办律师提供的文件和资料是完整、真实和有效的，无隐瞒、虚假、遗漏和误 导之处，其中文件资料为副本、复印件的，保证与正本或原件相符。 4. 本法律意见书仅供嘉事堂为进行本次股东大会之目的而使用，非经本所 同意，不得用作任何其他目的。 5. 承办律师同意将本法律意见书作为嘉事堂进行本次股东大会必备的法定 文件，随其他相关材料一起报送深圳证券交易所及进行公告，并依法对所出具的 法律意见承担责任。 第二节 法律意见书正文 北京市安理律师事务所（以下简称"本所"）接受嘉事堂药业股份有限公司 （以下简称"嘉事堂"或"公司"）委托，指派张晓光律师、王瑞欣律 ...

证券代码：002462 证券简称：嘉事堂 公告编号：2025-19 嘉事堂药业股份有限公司 2024年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 2. 中小投资者出席的总体情况 特别提示： 1．本次股东大会未出现否决提案的情形。 2．本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）嘉事堂2024年度股东大会于2025年5月19日下午3点在公司二楼会议室 召开。会议由公司董事长主持，本次股东大会按照会议议程，采用现场表决与网 络投票相结合的表决方式，审议了相关议案并作出决议。本次股东大会的召开符 合《公司法》和《公司章程》的有关规定，会议召开合法有效。 （二）会议出席情况 1. 股东总体出席情况 通过现场和网络投票的股东157人，代表股份120,362,414股，占公司有表决 权股份总数的41.2614％。 其中：通过现场投票的股东8人，代表股份117,697,475股，占公司有表决权 股份总数的40.3478％。 通过网络投票的股东149人，代表股份2,664,939股，占公司有表决权股份总 数的0.91 ...

Core Viewpoint - Jia Shitang aims to become a leading comprehensive service provider in pharmaceutical distribution and healthcare, focusing on meeting the medical needs of the public and fulfilling its responsibilities as a central enterprise [1] Group 1: Company Strategy and Vision - Jia Shitang has established a complete business system covering pharmaceutical wholesale, retail, logistics, and medical device supply chains, with a focus on secondary and tertiary hospitals, community medical centers, and chain pharmacies [1] - The company emphasizes its role in the "Healthy China" strategy and leverages the advantages of the China Everbright Group to enhance its position in the pharmaceutical industry [1][2] - The company aims to innovate and enhance its digital transformation in the pharmaceutical industry, optimizing supply chain management and logistics efficiency [3] Group 2: Financial Performance and Market Outlook - For the year 2024, Jia Shitang expects to achieve a revenue of 24.019 billion yuan and a net profit of 322 million yuan, maintaining a stable business foundation [2] - The pharmaceutical distribution industry in China is projected to continue expanding, driven by an aging population and increasing health awareness, leading to a growing demand for pharmaceuticals and high-value consumables [2] Group 3: Challenges and Innovations - The company is addressing challenges in the industry by focusing on digital transformation and exploring innovative cooperation models with internet pharmaceutical service providers [3] - Jia Shitang is actively exploring the use of drones for medical supply delivery in emergency situations to overcome ground transportation bottlenecks [3] Group 4: Future Development Goals - In 2025, Jia Shitang aims to achieve the goals of the "14th Five-Year Plan" and contribute to the global health sector by enhancing its information technology and resource potential [4] - The company plans to expand its rehabilitation medical business and develop its own health service brand, focusing on customer needs in the health service sector [4][5]

Stock Performance - Several stocks have shown significant gains, with notable performances including: - 恒天海龙 with a 10.07% increase over two days [2] - 晨曦航空 achieving a 19.96% rise on its first board [3] - 通易航天 with a remarkable 29.96% increase on its first board [3] - 新坐标 maintaining a 10.01% increase over four days [5] - 全筑股份 also showing a 10.00% increase over four days [9] Industry Trends - The robotics sector is gaining traction, with multiple companies experiencing stock price increases attributed to advancements in robotic technology and applications [4][5][7] - The AI computing industry is showing strong performance, as indicated by the positive financial results from companies in this sector, suggesting a sustained high level of industry activity [8] - The brain-computer interface (BCI) technology is gaining attention following FDA approval for Neuralink's device, which is aimed at aiding patients with severe communication disabilities [11] - The chemical industry is experiencing volatility in product prices, drawing market interest towards related companies [13] - The semiconductor industry is benefiting from increased investment and support for domestic high-end lithography machines, which is expected to boost the semiconductor equipment supply chain [16] - The real estate sector is reacting positively to the People's Bank of China's decision to lower housing loan interest rates, which is likely to stimulate market activity [18] Market Reactions - Stocks related to the ride-hailing industry are responding positively to the news of a partnership between autonomous driving company 小马智行 and Uber, with significant stock price increases observed [20][21] - The food and beverage sector is also seeing positive movements, influenced by the central bank's announcement of a new loan program aimed at boosting consumer spending [22][24] - The financial sector is reacting to the People's Bank of China's announcement of a series of monetary policy measures, including a reserve requirement ratio cut and interest rate adjustments [25][26]

A股医药商业板块异动拉升，嘉事堂封板涨停，瑞康医药、润达医疗、漱玉平民、合富中国、海王生物 等跟涨。 ...

暗盘资金正涌入这些股票，点击速看>>> 医药商业板块短线拉升，嘉事堂（002462）涨停，瑞康医药（002589）、润达医疗（603108）、漱玉平 民（301017）、合富中国（603122）、海王生物（000078）等跟涨。 ...

Market Overview - The Shanghai Composite Index is at 3305.11 points, above the annual line, with an increase of 0.80% [1] - The total trading volume of A-shares is 646.819 billion yuan [1] Stocks Breaking Annual Line - A total of 233 A-shares have surpassed the annual line today [1] - Notable stocks with significant deviation rates include: - Jinkai Biological Science and Technology (10.11%) - Disen Power (9.84%) - Hanbo High-tech (8.84%) [1] Stock Performance Details - The top stocks with their respective performance metrics are as follows: - Jinkai Biological: Price increased by 10.32%, turnover rate 13.55%, latest price 33.02 yuan [1] - Disen Power: Price increased by 10.04%, turnover rate 1.77%, latest price 4.93 yuan [1] - Hanbo High-tech: Price increased by 9.42%, turnover rate 3.54%, latest price 15.33 yuan [1] - Other notable stocks include: - Jiashitang (9.97%, 3.57%, 13.13 yuan) - Sanmu Group (9.94%, 7.78%, 3.54 yuan) [1] Additional Stocks with Minor Deviations - Stocks with smaller deviation rates that have just crossed the annual line include: - Yongqing Environmental Protection - Dongjian Technology - Aishide [1]

股票代码：002462 股票简称：嘉事堂 公告编号：2025-18 嘉事堂药业股份有限公司 估值提升计划 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、估值提升计划的触及情形及审议程序 1. 触及情形 根据中国证监会发布的《上市公司监管指引第 10 号——市值管理》（以下 简称"《指引》"），长期破净公司应当制定上市公司估值提升计划，并经董 事会审议后披露。公司股票自 2024 年 1 月 17 日至 2025 年 1 月 16 日,连续 12 个月每个交易日收盘价均低于最近一期经审计的每股归属于上市公司股东的净 资产。其中 2024 年 1 月 17 日至 2024 年 4 月 29 日，最高收盘价 13.70 元，低 于公司 2022 年经审计的归属于上市公司股东的每股净资产 13.98 元；2024 年 4 月 30 日至 2025 年 1 月 16 日，最高收盘价 14.36 元，低于公司 2023 年经审计 的归属于上市公司股东的每股净资产 14.54 元，属于《指引》定义的"长期破 净公司"，应当制定上市公司估值提升计划，并经董事会审议后对外 ...